Board Meeting Outcomes

The Board of Directors meeting was held on Friday, November 13, 2026, starting at 4:10 PM and concluding at 5:05 PM. The board approved:

1. Un-Audited Financial Results (standalone and consolidated) for the 2nd quarter and half year ended September 30, 2026 of FY 2026-27

2. The expiration of Mr. Rakesh Mohan's term as Non-Executive Independent Director on November 10, 2026, after completing two consecutive terms of 5 years each (total 10 years)

Financial Results - Standalone (Rs. in Lakhs)

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹1,922.48 (vs. ₹2,351.76 in Q2 FY26)
  • Other Income: ₹118.27
  • Total Income: ₹2,040.75
  • Profit before Tax: ₹25.39 (vs. ₹109.58 in Q2 FY26)
  • Tax Expense: ₹6.13
  • Profit after Tax: ₹19.26 (vs. ₹78.90 in Q2 FY26)
  • Basic EPS: ₹0.19 (vs. ₹0.77 in Q2 FY26)

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹3,821.07 (vs. ₹4,615.96 in H1 FY26)
  • Other Income: ₹141.03
  • Total Income: ₹3,962.10
  • Profit before Tax: ₹50.22 (vs. ₹150.59 in H1 FY26)
  • Tax Expense: ₹(20.10) credit
  • Profit after Tax: ₹70.32 (vs. ₹107.52 in H1 FY26)
  • Basic EPS: ₹0.69 (vs. ₹1.05 in H1 FY26)

Financial Results - Consolidated (Rs. in Lakhs)

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹1,922.48
  • Other Income: ₹118.84
  • Total Income: ₹2,041.32
  • Profit before Tax: ₹29.92
  • Tax Expense: ₹6.13
  • Profit after Tax: ₹23.79
  • Basic EPS: ₹0.23

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹3,821.07
  • Other Income: ₹141.60
  • Total Income: ₹3,962.67
  • Profit before Tax: ₹50.00
  • Tax Expense: ₹(20.10) credit
  • Profit after Tax: ₹70.10
  • Basic EPS: ₹0.68

Subsidiary Information

The consolidated results include two foreign subsidiaries:

1. Sunil Healthcare Mexico Sa De CV

2. Sunil Healthcare North America LLC

These subsidiaries had total assets of ₹108.16 lakhs as at September 30, 2026, with minimal revenue (₹Nil for both quarter and half year) and net profit after tax of ₹4.53 lakhs and ₹(0.22) lakhs respectively for the quarter and half year ended September 30, 2026. Management considers these subsidiaries not material to the Group.

Balance Sheet Position (As at September 30, 2026)

Standalone:

  • Total Assets: ₹17,166.15 lakhs
  • Equity Share Capital: ₹1,025.48 lakhs
  • Other Equity: ₹6,082.94 lakhs
  • Total Borrowings: ₹6,615.74 lakhs (Non-current: ₹1,937.84 lakhs, Current: ₹4,677.90 lakhs)

Consolidated:

  • Total Assets: ₹17,387.41 lakhs
  • Equity Share Capital: ₹1,025.48 lakhs
  • Other Equity: ₹6,261.25 lakhs

Cash Flow Statement (Half Year Ended September 30, 2026)

Standalone:

  • Net Cash used in Operating Activities: ₹(420.98) lakhs
  • Net Cash used in Investing Activities: ₹(325.80) lakhs
  • Net Cash from Financing Activities: ₹747.78 lakhs
  • Net Increase in Cash: ₹1.00 lakh

Additional Information

The company operates in a single business segment - sale of capsules. The company has exercised the option permitted under section 200 of the Income Tax Act, 2025 as introduced by the Taxation Laws (Amendment) Ordinance, 2019 for tax calculations.